Envestnet Asset Management Inc. Sells 5,911 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Envestnet Asset Management Inc. lessened its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 6.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 84,372 shares of the company’s stock after selling 5,911 shares during the quarter. Envestnet Asset Management Inc.’s holdings in TransMedics Group were worth $5,261,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in shares of TransMedics Group by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company’s stock valued at $226,700,000 after purchasing an additional 40,860 shares in the last quarter. Geode Capital Management LLC boosted its position in TransMedics Group by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 772,744 shares of the company’s stock valued at $48,191,000 after buying an additional 8,954 shares during the last quarter. Emerald Advisers LLC increased its stake in shares of TransMedics Group by 146.3% in the 4th quarter. Emerald Advisers LLC now owns 371,711 shares of the company’s stock valued at $23,176,000 after buying an additional 220,804 shares during the period. Norges Bank bought a new stake in shares of TransMedics Group during the fourth quarter worth $22,861,000. Finally, Vaughan Nelson Investment Management L.P. raised its position in shares of TransMedics Group by 9.9% during the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company’s stock worth $22,547,000 after acquiring an additional 32,605 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $91.21 on Wednesday. The stock has a market cap of $3.09 billion, a PE ratio of 97.03 and a beta of 2.14. The stock has a 50-day moving average of $73.24 and a 200-day moving average of $78.72. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37.

Analyst Ratings Changes

A number of analysts recently commented on TMDX shares. Canaccord Genuity Group reiterated a “buy” rating and issued a $104.00 price objective on shares of TransMedics Group in a research report on Tuesday, March 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research note on Wednesday, March 26th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, TransMedics Group currently has an average rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.